Dr. Paul Rothman, a distinguished physician, scientist, educator and academic health care leader, is the 14th dean of the Johns Hopkins University School of Medicine and second chief executive officer of Johns Hopkins Medicine. He is also a professor of medicine and molecular biology and genetics.
A rheumatologist and molecular immunologist, Dr. Rothman studies the role of immune system molecules known as cytokines and their development of blood cells called leukocytes. Abnormal development of these blood cells can lead to leukemia. He also studies the role of cytokines in immune system responses to asthma and allergies.
Dr. Rothman is an elected member of the American Association for the Advancement of Science, the American College of Physicians, the Council of the Association of American Physicians and the American Society of Clinical Investigation. He has served as a member of the National Institutes of Health Immunologic Sciences Study Section, the Israel Cancer Research Fund International Scientific Advisory Board, the American Academy of Allergy, Asthma and Immunology Grant Review Committee, and the American Thoracic Society Asthma Immunology and Inflammation Program Committee.
His awards include a James S. McDonnell Foundation Career Development Award, Pfizer Scholars Award, Pew Scholars Award, Leukemia Society of America Scholar Award and Pharmacia Allergy Research Foundation International Award.
A 1980 Phi Beta Kappa graduate of the Massachusetts Institute of Technology, Dr. Rothman earned his medical degree from Yale University in 1984. He completed his residency training at Columbia-Presbyterian Medical Center and a postdoctoral fellowship at Columbia University.
Jennifer Elisseeff, Ph.D.
Dr. Jennifer Elisseeff is the Jules Stein Chair in Ophthalmology at the Wilmer Eye Institute and director of the Translational Tissue Engineering Center in collaboration with the Department of Biomedical Engineering. She also is a professor of orthopedic surgery, chemical and biological engineering, and materials science and engineering.
A renowned expert and innovator in tissue regeneration, Dr. Elisseeff has published over 110 articles and book chapters and has given over 130 national and international invited lectures.
In 2004, Dr. Elisseeff cofounded Cartilix Inc., a startup that translated adhesive and biomaterial technologies for treating orthopedic disease, acquired by Biomet Inc. in 2009. In 2009, she also founded Aegeria Soft Tissue and Tissue Repair, startups focused on soft tissue regeneration and wound healing. She serves on the scientific advisory boards of Bausch and Lomb, Kythera Biopharmaceutical and Cellular Bioengineering Inc. Dr. Elisseeff’s awards include the Carnegie Mellon Young Alumni Award, Arthritis Investigator Award from the Arthritis Foundation, and Yasuda Award from the Society of Physical Regulation in Medicine and Biology. She was named by Technology Review magazine as a top innovator under 35 in 2002 and her research was cited among the top 10 technologies to change the future. In 2008, she was elected a fellow of the American Institute for Medical and Biological Engineering and a Young Global Leader in the World Economic Forum.
Dr. Elisseeff received her bachelor’s degree in chemistry from Carnegie Mellon University and her Ph.D. in medical engineering from the Harvard-MIT Division of Health Sciences and TechnologyShe was a fellow at the National Institute of General Medical Sciences Pharmacology Research Associate Program, where she worked in the National Institute of Dental and Craniofacial Research.
In 1991, Dr. McVeigh founded the Medical Imaging Laboratory in the Department of Biomedical Engineering. Among the many novel MR imaging techniques developed there werethere were several that form the foundation of the modern cardiac MRI exam. Dr. McVeigh's laboratory also demonstrated the ability of MRI to evaluate the benefit of cardiac resynchronization therapy (CRT) in the failing heart; these studies were seminal in understanding how CRT should be used.
In 1999, Dr. McVeigh joined the Laboratory of Cardiac Energetics at the National Institutes of Health to develop a research program in cardiovascular interventional MRI. Working with clinical colleagues, Dr. McVeigh's laboratory demonstrated numerous novel applications for the first time, including the first MRI-guided injections of therapeutic agents directly into heart muscle, the first simultaneous electrical and mechanical measurements of cardiac function with MR, and the first MR-guided aortic valve replacement in the beating heart.
Dr. McVeigh has published more than 200 peer-reviewed papers and has lectured around the world.
After earning both his undergraduate and doctoral degrees at the University of Toronto, he joined the radiology faculty at the Johns Hopkins University School of Medicine.
William Nelson, M.D., Ph. D.
Dr. William G. Nelson is the Marion I. Knott Professor of Oncology and Director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He is a professor of urology, pharmacology, medicine, pathology and radiation oncology at the Johns Hopkins University School of Medicine and has a joint appointment in environmental health sciences at the Johns Hopkins University Bloomberg School of Public Health.
Dr. Nelson directs a research laboratory focused on discovering new strategies for prostate cancer treatment and prevention. With Johns Hopkins colleagues, he discovered the most common acquired genome defect in prostate cancer, a finding that has led to new diagnostic tests for the disease and has fueled new drug discovery for disease treatment, now ongoing at the Johns Hopkins Cancer Center.
A recognized leader in cancer research, Dr. Nelson worked to reengineer translational cancer science across the nation and helped to author a landmark report as one of three co-chairs of the National Cancer Institute’s Translational Research Working Group. He has also been a member of the Scientific Advisory Boards of several companies focused on the development of new technologies and treatments for cancer, a co-chair of the Scientific Advisory Committee for Stand Up 2 Cancer, and a member of the scientific advisory boards/committees for a number of foundations, including the Prostate Cancer Foundation, the Kimmel Scholars and the V Foundation.
Dr. Nelson completed his M.D. and Ph.D. training at the Johns Hopkins University School of Medicine, earning honors for both research and clinical excellence. He also completed his residency training and medical oncology fellowship at Johns Hopkins.